6 April 2021 - Janssen said Tuesday that the government began providing health insurance benefits for its prostate cancer therapy Zytiga (abiraterone acetate) as a first-line treatment for high-risk metastatic hormone-sensitive prostate cancer.

Patients who satisfy at least two among the following conditions - Gleason score of eight, three or more lesions identified through bone scans, and visceral metastases confirmed by computed tomography or magnetic resonance imaging – can benefit health insurance coverage for Zytiga in combination with prednisolone and androgen deprivation therapy.

Read Korea Biomedical Review article